Leading Health Organizations Recommend the Use of Hand Dryers
30.6.2020 23:15:00 EEST | Business Wire | Press release
The topic of hygiene has come to the forefront in mainstream media as reopening plans are introduced around the globe. While leading health organizations like the World Health Organization (WHO), and Centers for Disease Control and Prevention (CDC), recommend the use of hand dryers, misinformation about them remains online, and continues to be quoted and perpetuated. Leaders from Excel Dryer, manufacturer of XLERATOR® Hand Dryers, wish to deliver a message to educate the professionals, consultants and government officials who are creating reopening guidelines, and the general public, especially in times of COVID-19: Excel hand dryers are a safe, hygienic touchless solution and an effective way to achieve completely dry hands, a critical part of proper hand hygiene, the top defense against the spread of germs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630006010/en/
Leading Health Organizations Recommend the Use of Hand Dryers (Graphic: Business Wire)
Kelly Reynolds, Ph.D., Professor and Department Chair at the Mel & Enid Zuckerman College of Public Health at the University of Arizona, offered an explanation as to the root of these misconceptions, stating that, “Consumers may only read [sensationalized] headlines which can influence public opinion toward biased or erroneous conclusions, [but] the fact is, the breadth of data available does not favor one hand drying method as being more hygienic or safer.”
Excel hand dryers provide a touchless hand drying solution to help prevent potential cross-contamination between restroom surfaces and wet hands. All dryers in Excel’s line are hygienic, but dryers with HEPA have been proven to add another level of protection. Viral efficiency testing conducted by the preeminent independent air media and filter testing company, LMS Technologies in April of 2020 found that XLERATOR®, XLERATOReco ® and XLERATORsync® Hand Dryers with HEPA Filtration Systems remove 99.999 percent of viruses from the airstream.
William Gagnon, vice president of marketing and sales at Excel Dryer, wishes to correct misinformation and biases about hand dryers. “Hand dryers are hygienic and have been used to properly dry hands for decades. In addition to top health organizations recommending their use, hand dryers also provide significant benefits over paper that are undisputable. For example, our recent test results prove XLERATOR hand dryers with HEPA Filtration Systems remove 99.999 percent of viruses from the airstream, something paper will never be able to do.”
Conversely, paper towels may not be as hygienic as the public believes. One independent study showed 17 species of bacteria on unused, recycled paper towels, including Bacillus, which can cause food poisoning. After their use, damp paper towels are a breeding ground for viruses and bacteria in and around trash receptacles and can be used to clog toilets and sinks creating a very unhygienic restroom environment. If the paper towels are out of stock, visitors cannot dry their hands at all, and wet hands have been shown to be 1,000 times more likely to transfer germs than dry hands.
Gagnon concluded, “I encourage members of the public and those individuals charged with the creation of guidelines, reopening plans or facilities operations, to dive deeper into news articles and hygiene studies rather than simply believing sensationalized, click-bait headlines born from biased results. Hand dryers are safe and hygienic. They dry hands completely, and are a top defense against the spread of germs.”
About Excel Dryer, Inc.
Excel Dryer has been manufacturing the finest American-made hand dryers for more than 50 years. The family-owned and -operated company revolutionized the industry with the invention of the patented XLERATOR® Hand Dryer that created the high-speed, energy-efficient hand dryer category and set a new standard for performance, reliability and customer satisfaction. Excel Dryer prides itself on offering the best customer service and making hygienic, cost-effective and sustainable products people can depend on. Available for distribution worldwide, Excel Dryer products can be purchased through an established network of sales representatives who call on more than 5,000 distributors globally. Learn more about Excel Dryer at exceldryer.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630006010/en/
Contact information
Lisa Twarog or Michelle Abdow
(Office) 413-787-1133
ltwarog@marketmentors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
